Related references
Note: Only part of the references are listed.Effects of Organic Acids on Drug Release From Ternary Polypeptide Nanoparticles Entrapping Carfilzomib
Sharonda Jackson et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2022)
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
Huanjie Yang et al.
SEMINARS IN CANCER BIOLOGY (2021)
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma
Serena Rocchi et al.
HEMATOLOGICAL ONCOLOGY (2021)
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience
Nadjoua Maouche et al.
LEUKEMIA & LYMPHOMA (2021)
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma
Shambavi Richard et al.
EXPERT REVIEW OF HEMATOLOGY (2021)
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
Philippe Moreau et al.
LANCET (2021)
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
Philippe Moreau et al.
FUTURE ONCOLOGY (2020)
Proteasome Inhibitors for the Treatment of Multiple Myeloma
Shigeki Ito
CANCERS (2020)
Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials
Somedeb Ball et al.
ANNALS OF HEMATOLOGY (2020)
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
G. R. Tundo et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Meletios Dimopoulos et al.
LANCET (2020)
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma
Thierry Facon et al.
BLOOD ADVANCES (2020)
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma
Xavier Leleu et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Preparation and optimization of poly (lactic acid) nanoparticles loaded with fisetin to improve anti-cancer therapy
Chunlai Feng et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2019)
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2019)
H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth
Min Jae Lee et al.
SCIENTIFIC REPORTS (2019)
Carfilzomib for relapsed and refractory multiple myeloma
K. Groen et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin
Panagiotis Efentakis et al.
BLOOD (2019)
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
A. Besse et al.
LEUKEMIA (2018)
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study
Philippe Moreau et al.
LANCET ONCOLOGY (2018)
Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis
Chintan Shah et al.
LEUKEMIA & LYMPHOMA (2018)
Next-generation proteasome inhibitors for cancer therapy
Ji Eun Park et al.
TRANSLATIONAL RESEARCH (2018)
Ixazomib for the treatment of multiple myeloma
Paul G. Richardson et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R. Hajek et al.
LEUKEMIA (2017)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Proteasome inhibitors in cancer therapy
Elisabet E. Manasanch et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Proteasome inhibitors: structure and function
Ana T. Nunes et al.
SEMINARS IN ONCOLOGY (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
Xiaoyan Feng et al.
CLINICAL CANCER RESEARCH (2017)
Cardiac and renal complications of carfilzomib in patients with multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD ADVANCES (2017)
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
James R. Berenson et al.
BLOOD (2016)
High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design
Kimberly Carmony et al.
CHEMBIOCHEM (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design
Jil Schrader et al.
SCIENCE (2016)
Spotlight on ixazomib: potential in the treatment of multiple myeloma
Barbara Muz et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma
Ali McBride et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2015)
Reprogramming of human cancer cells to pluripotency for models of cancer progression
Jungsun Kim et al.
EMBO JOURNAL (2015)
Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Kyriakos P. Papadopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
S. K. Kumar et al.
BLOOD CANCER JOURNAL (2015)
Current treatment landscape for relapsed and/or refractory multiple myeloma
Meletios A. Dimopoulos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Polymer Micelle Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic Stability and Anticancer Efficacy in Human Multiple Myeloma and Lung Cancer Cell Lines
Lin Ao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
Nikoletta Lendvai et al.
BLOOD (2014)
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert et al.
CLINICAL CANCER RESEARCH (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Yi Xiao et al.
PLOS ONE (2014)
An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
Massimo Offidani et al.
OncoTargets and Therapy (2014)
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
Michael Wang et al.
BLOOD (2013)
Targeting the ubiquitin proteasome system in haematological malignancies
Lisa J. Crawford et al.
BLOOD REVIEWS (2013)
Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
Ruben Niesvizky et al.
CLINICAL CANCER RESEARCH (2013)
U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma
Thomas M. Herndon et al.
CLINICAL CANCER RESEARCH (2013)
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
David Siegel et al.
HAEMATOLOGICA (2013)
Carfilzomib: a novel agent for multiple myeloma
Kimberly Redic
JOURNAL OF PHARMACY AND PHARMACOLOGY (2013)
Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines
Kenneth C. Anderson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma
Jason M Steele
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2013)
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij et al.
BLOOD (2012)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
Melissa Alsina et al.
CLINICAL CANCER RESEARCH (2012)
An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
Sundar Jagannath et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Therapeutic targeting of cancer cell cycle using proteasome inhibitors
Namrata Rastogi et al.
CELL DIVISION (2012)
Role of carfilzomib in the treatment of multiple myeloma
Rashid Z. Khan et al.
EXPERT REVIEW OF HEMATOLOGY (2012)
Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats
Jinfu Yang et al.
DRUG METABOLISM AND DISPOSITION (2011)
The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
Peter Walter et al.
SCIENCE (2011)
Proteasome inhibitors in cancer therapy
Lisa J. Crawford et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2011)
Relapsed Multiple Myeloma
Sagar Lonial
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic
Alison L. Allan et al.
JOURNAL OF ONCOLOGY (2010)
A monoclonal gammopathy precedes multiple myeloma in most patients
Brendan M. Weiss et al.
BLOOD (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
Cyclin D1 Degradation Is Sufficient to Induce G1 Cell Cycle Arrest despite Constitutive Expression of Cyclin E2 in Ovarian Cancer Cells
Chioniso Patience Masamha et al.
CANCER RESEARCH (2009)
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Owen A. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells
Hongjuan Dong et al.
LEUKEMIA & LYMPHOMA (2009)
p21 in cancer: intricate networks and multiple activities
Tarek Abbas et al.
NATURE REVIEWS CANCER (2009)
Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology
Alan L. Schwartz et al.
Annual Review of Pharmacology and Toxicology (2008)
Noxa: at the tip of the balance between life and death
C. Ploner et al.
ONCOGENE (2008)
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib
D. A. Fennell et al.
ONCOGENE (2008)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib
Alex Hemeryck et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma
Patricia Gomez-Bougie et al.
CANCER RESEARCH (2007)
PCNA, the maestro of the replication fork
George-Lucian Moldovan et al.
CELL (2007)
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma
Christian Jakob et al.
BLOOD (2007)
Nuclear factor-κ13 in development, prevention, and therapy of cancer
Carter Van Waes
CLINICAL CANCER RESEARCH (2007)
Drug discovery in the ubiquitin-proteasome system
Grzegorz Nalepa et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis
M Bazzaro et al.
CANCER RESEARCH (2006)
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate
AF Kisselev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Structural complexity in ubiquitin recognition
JW Harper et al.
CELL (2006)
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells
JZ Qin et al.
CANCER RESEARCH (2005)
Recruitment of DNA methyltransferase I to DNA repair sites
O Mortusewicz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
C Nakanishi et al.
NATURE REVIEWS CANCER (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells
XY Pei et al.
LEUKEMIA (2003)
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells
AH Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
For whom the bell tolls: protein quality control of the endoplasmic reticulum and the ubiquitin-proteasome connection
Z Kostova et al.
EMBO JOURNAL (2003)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment
P Sonneveld et al.
EUROPEAN JOURNAL OF CANCER (2003)
The role of the ubiquitination-proteasome pathway in breast cancer - Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
RZ Orlowski et al.
BREAST CANCER RESEARCH (2003)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
N Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells
V Marshansky et al.
JOURNAL OF IMMUNOLOGY (2001)
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
AS Baldwin
JOURNAL OF CLINICAL INVESTIGATION (2001)
Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2000)
Share Paper
